Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of ...
New financials from high-street staple Specsavers reflect record demand and another year of commendable growth, with group revenue climbing 7.5% to £4.18bn for the year ending February 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback